Eli Lilly stock price forecast: consolidation after recovery as LLY holds above long-term support

Traders Union
All News
Business & Wealth
Companies
Eli Lilly rises 1.42% today

Highlights

LLY remains under short- and medium-term pressure as it trades below its key moving averages, but finds support above its long-term trendline.
Technical signals are mixed, showing negative momentum and weak trend strength despite moderate price recovery and limited volatility.
Price is expected to consolidate between $913 and $920 next week, with a bullish breakout above $921 targeting resistance near $980 and major support at $894.

The company shared news of the clinical trial results on social media. Eli Lilly provided a link for further information.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

LLY ($915.81) is trading below the SMA-20 ($971.95) and SMA-50 ($1,014.69), indicating continued short- and medium-term pressure from sellers, but remains firmly above the long-term SMA-200 ($894.68), suggesting underlying support persists on a larger time frame. The Ichimoku Kijun on D1 stands at $980.03, which acts as immediate resistance near the upper boundary of current price action.

Momentum indicators on D1 give a mixed picture: MACD remains negative and signals "Sell," while ADX at 13.24 stays neutral, pointing to a lack of trend strength. The RSI at 35.14 and CCI at -98.79 are both in "Sell" zones, with Stoch RSI showing "Strong Buy" but still near oversold territory. BBP at -20.88 signals sellers are dominant intraday, despite pockets of buying interest in short bursts. LLY is trading at $915.81, up from $905.37 a week ago, reflecting a 1.15% gain. The price sits in the upper part of this week's range, and weekly volatility stands at 3.48%. The overall weekly movement suggests moderate recovery from the lows but with indicators pointing to an unresolved tug-of-war between buyers and sellers. In today's session, LLY is showing a solid 1.42% gain from the previous close.

For the coming week, the expected price range is $913 to $920, anchored around typical volatility and in line with the provided weekly average. Relative to the $624.40 52-week low and $1,133.95 high, this keeps LLY near the upper third of its annual corridor. The probability of a price increase is moderate, while the probability of decline is less likely, given the "Buy" signal from ADX-W1 and "Strong Buy" from MACD-W1, but offset by a "Sell" from RSI-W1 and mixed MA-50-W1 signals. Baseline scenario: price consolidates sideways within the corridor. Bullish scenario: a break above $921 targets the Kijun resistance near $980. Bearish scenario: a close below near-term support at $894 (SMA-200) exposes the next downside.

In a recent review, analysts highlighted Eli Lilly's strong growth prospects driven by its innovations in metabolic disease treatment and deep drug development pipeline. With current developments, investors should pay close attention to whether the stock can sustain momentum above key support levels, as this will be crucial in determining its near-term direction.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.